Miwa K - Search Results

1

Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801).

Miwa K, Oki E, Emi Y, Saeki H, Kusumoto T, Akagi Y, Ogata Y, Samura H, Tokunaga S, Ishikawa H, Tanaka T, Sueyoshi S, Higashi H, Matsuda H, Touyama T, Maehara Y; Kyushu Study Group of Clinical Cancer. Miwa K, et al. Int J Clin Oncol. 2016 Feb;21(1):110-7. doi: 10.1007/s10147-015-0850-3. Epub 2015 Jun 3. Int J Clin Oncol. 2016. PMID: 26037783 Clinical Trial.

2

Temporary stenting for malignant tracheal stenosis due to esophageal cancer: a case report.

Miwa K, Matsuo T, Takamori S, Sueyoshi S, Mitsuoka M, Fujita H, Hayashi A, Shirouzu K. Miwa K, et al. Jpn J Clin Oncol. 2002 Jan;32(1):27-9. doi: 10.1093/jjco/hyf004. Jpn J Clin Oncol. 2002. PMID: 11932359

3

Repeat pulmonary resection for isolated recurrent lung metastases yields results comparable to those after first pulmonary resection in colorectal cancer.

Ogata Y, Matono K, Hayashi A, Takamor S, Miwa K, Sasatomi T, Ishibashi N, Shida S, Shirouzu K. Ogata Y, et al. Among authors: miwa k. World J Surg. 2005 Mar;29(3):363-8. doi: 10.1007/s00268-004-7537-7. World J Surg. 2005. PMID: 15706447

4

Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.

Ajima H, Ogata H, Fujita K, Miwa K, Sunakawa Y, Mizuno K, Ishida H, Yamashita K, Nakayama H, Kawara K, Takahashi H, Sasaki Y. Ajima H, et al. Among authors: miwa k. Jpn J Clin Oncol. 2010 Jul;40(7):634-8. doi: 10.1093/jjco/hyq029. Jpn J Clin Oncol. 2010. PMID: 20587616

5

UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.

Sunakawa Y, Ichikawa W, Fujita K, Nagashima F, Ishida H, Yamashita K, Mizuno K, Miwa K, Kawara K, Akiyama Y, Araki K, Yamamoto W, Miya T, Narabayashi M, Ando Y, Hirose T, Saji S, Sasaki Y. Sunakawa Y, et al. Among authors: miwa k. Cancer Chemother Pharmacol. 2011 Aug;68(2):279-84. doi: 10.1007/s00280-010-1485-8. Epub 2010 Oct 19. Cancer Chemother Pharmacol. 2011. PMID: 20957480

6

Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.

Ishida H, Fujita K, Akiyama Y, Sunakawa Y, Yamashita K, Mizuno K, Miwa K, Kawara K, Ichikawa W, Ando Y, Saji S, Sasaki Y. Ishida H, et al. Among authors: miwa k. Jpn J Clin Oncol. 2011 May;41(5):617-23. doi: 10.1093/jjco/hyr010. Epub 2011 Feb 9. Jpn J Clin Oncol. 2011. PMID: 21310730

7

Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer.

Akiyama Y, Fujita K, Ishida H, Sunakawa Y, Yamashita K, Kawara K, Miwa K, Saji S, Sasaki Y. Akiyama Y, et al. Among authors: miwa k. Drug Metab Pharmacokinet. 2012;27(3):325-35. doi: 10.2133/dmpk.dmpk-11-rg-128. Epub 2011 Dec 27. Drug Metab Pharmacokinet. 2012. PMID: 22201120 Free article.

8

A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28.

Sunakawa Y, Fujita K, Ichikawa W, Ishida H, Yamashita K, Araki K, Miwa K, Kawara K, Akiyama Y, Yamamoto W, Nagashima F, Saji S, Sasaki Y. Sunakawa Y, et al. Among authors: miwa k. Oncology. 2012;82(4):242-8. doi: 10.1159/000337225. Epub 2012 Apr 12. Oncology. 2012. PMID: 22508373 Clinical Trial.

9

Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer.

Sasaki T, Fujita K, Sunakawa Y, Ishida H, Yamashita K, Miwa K, Saji S, Kato Y, Sasaki Y. Sasaki T, et al. Among authors: miwa k. Int J Clin Oncol. 2013 Aug;18(4):735-42. doi: 10.1007/s10147-012-0425-5. Epub 2012 May 26. Int J Clin Oncol. 2013. PMID: 22638624

10

Successful treatment with s-1 and oxaliplatin combination therapy in an elderly patient with metastatic colorectal cancer initially presenting with membranous nephropathy.

Matsunaga M, Miwa K, Oka Y, Ushijima T, Yuge K, Fukahori M, Katagiri M, Akagi Y. Matsunaga M, et al. Among authors: miwa k. Case Rep Oncol. 2015 Apr 28;8(1):212-6. doi: 10.1159/000382119. eCollection 2015 Jan-Apr. Case Rep Oncol. 2015. PMID: 26034482 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,241 results

Search Page

Filters